Reply: Optimal Positioning of Novel Heart Failure Pharmacotherapies: The Case of Vericiguat

JACC Heart Fail. 2021 May;9(5):403. doi: 10.1016/j.jchf.2021.03.001.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Heart Failure* / drug therapy
  • Heterocyclic Compounds, 2-Ring*
  • Humans
  • Pyrimidines

Substances

  • Heterocyclic Compounds, 2-Ring
  • Pyrimidines
  • vericiguat